HAVN Life Sciences Inc.
HAVLF
$0.001
$0.000.00%
OTC PK
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -148.90% | 975.00% | 594.74% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -148.90% | 975.00% | 594.74% | -- | -- |
| Cost of Revenue | 288.97% | 567.72% | 730.23% | -- | -- |
| Gross Profit | -1,443.48% | 1,531.18% | 418.18% | -- | -- |
| SG&A Expenses | -69.07% | -76.94% | -47.96% | -79.95% | -63.14% |
| Depreciation & Amortization | -99.90% | -99.91% | -83.93% | -93.98% | -88.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -67.29% | -70.16% | -47.95% | -81.46% | -67.05% |
| Operating Income | 66.24% | 80.20% | 51.02% | 84.03% | 67.46% |
| Income Before Tax | 70.30% | 60.44% | 62.25% | -2.72% | 83.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.30% | 60.44% | 62.25% | -2.72% | 83.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.30% | 60.44% | 62.25% | -2.72% | 83.12% |
| EBIT | 66.24% | 80.20% | 51.02% | 84.03% | 67.46% |
| EBITDA | 63.58% | 79.14% | 48.66% | 78.88% | 62.01% |
| EPS Basic | 87.03% | 72.88% | 72.86% | 33.03% | 89.82% |
| Normalized Basic EPS | 84.76% | 85.07% | 73.36% | 85.52% | 90.55% |
| EPS Diluted | 87.03% | 74.18% | 72.86% | 33.03% | 89.82% |
| Normalized Diluted EPS | 84.76% | 85.07% | 73.36% | 85.52% | 90.55% |
| Average Basic Shares Outstanding | 128.90% | 45.90% | 39.10% | 53.40% | 65.87% |
| Average Diluted Shares Outstanding | 128.90% | 45.90% | 39.10% | 53.40% | 65.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |